We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close


3 Trial Losses Won't Doom Xarelto Patients

Law360, New York (August 23, 2017, 12:47 PM EDT) -- After a hat trick of defense wins for Johnson & Johnson unit Janssen Pharmaceuticals Inc. and Bayer HealthCare Pharmaceuticals Inc. in bellwether trials over blood thinner Xarelto, consumers face an uphill — but not impossible — task of turning the tide in their favor.

So far, consumers in three bellwether trials have been unable to persuade jurors that Bayer and Janssen didn’t adequately instruct their treating physicians about the risks of dangerous internal bleeding associated with the blood thinner. Attorneys noted that a string of victories...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.